Company · founded 1998
Planet Biotechnology (United States)
Hayward, United States · planetbiotechnology.com
- Citations, last 5 years
- 39
- Works, last 5 years
- 15
- h-index
- 25
- Scientists listed
- 1
- Grants since 2016
- 24
Grants received
2024–2026 · research · R41
A broad spectrum anti-gonorrhea immunotherapeutic
Lisa Ann Lewis · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Bispecific antibody for topical administration to prevent gonorrhea
Sanjay Ram · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2026 · research · R41
Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2027 · research · R41
Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2026 · research · R41
A broad spectrum anti-gonorrhea immunotherapeutic
Jutamas Shaughnessy · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2027 · research · R43
Bispecific antibody for topical administration to prevent gonorrhea
Sanjay Ram · Planet Biotechnology (United States) · funded by National Institutes of Health
2024–2027 · research · R43
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Recombinant Fc fusions for treatment of uropathogenic E. coli
Evgeni Veniaminovic Sokurenko · Planet Biotechnology (United States) · funded by National Institutes of Health
2020–2022 · research · R41
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2020–2022 · research · R41
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2020–2025 · research · R44
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
Yi-Pin Lin · Planet Biotechnology (United States) · funded by National Institutes of Health
2020–2024 · research · R44
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
Yi-Pin Lin · Planet Biotechnology (United States) · funded by National Institutes of Health
2019–2023 · research · R44
An immunotherapeutic to prevent gonorrhea
Sanjay Ram · Planet Biotechnology (United States) · funded by National Institutes of Health
2019 · grant · Innovation
Planet Labs Inc. 2019
Planet Biotechnology (United States) · funded by Rockefeller Foundation
2019–2022 · research · R44
An immunotherapeutic to prevent gonorrhea
Sanjay Ram · Planet Biotechnology (United States) · funded by National Institutes of Health
2019–2020 · research · R44
An immunotherapeutic to prevent gonorrhea
Sanjay Ram · Planet Biotechnology (United States) · funded by National Institutes of Health
2018–2019 · research · R43
An immunoadhesin therapy for glioblastoma targeting CD97
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2017–2018 · research · R41
A novel anti-gonorrhea immunotherapeutic
Sanjay Ram · Planet Biotechnology (United States) · funded by National Institutes of Health
2017–2018 · research · R43
A mucosally targeted MERS-CoV vaccine produced in plants
Keith Wycoff · Planet Biotechnology (United States) · funded by National Institutes of Health
2016 · grant · Standard Grant
SBIR Phase I: Development and Evaluation of Novel Polymeric Sheet Membranes for Membrane Bioreactors
Subir Bhattacharjee · Planet Biotechnology (United States) · funded by National Science Foundation